Recor Medical Reports 19.6 mmHg Blood Pressure Reduction with Paradise System in Six Months

Recor Medical and its parent company Otsuka Medical Devices announced in a press release that new real-world clinical data presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference demonstrated a significant blood pressure reduction using the Paradise System for renal denervation.

According to the results from the Global Paradise System (GPS) registry, patients experienced a 19.6 mmHg decrease in systolic office blood pressure after six months of treatment with the ultrasound-based Paradise system. The analysis of pooled data from the global RADIANCE study program also showed a sustained systolic blood pressure reduction of 15.7 mmHg after 24 months.

The Paradise uRDN system is a device-based adjunctive therapy for patients with uncontrolled or resistant hypertension whose blood pressure remains high despite lifestyle modifications and medication.